Navigation Links
Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension

Next Generation Renin Inhibitor to Continue Phase II Profiling in Diabetic Patients


BASEL/Switzerland and BRIDGEWATER NJ/USA, 28 June 2007-Speedel (SWX: SPPN) today announced that it has reached another significant milestone in the development of its family of renin inhibitors with the successful completion of a Phase IIa proof-of-concept clinical trial with SPP635 for the treatment of hypertension. Based on these positive results, the company is to continue developing SPP635 in Phase II in a special population of diabetic patients with mild-to-moderate hypertension. This compound is the first of a next generation of renin inhibitors following Speedel's lead product SPP100 (aliskiren, Tekturna/Rasilez[1]), which is partnered with Novartis and recently obtained US marketing approval from the FDA and a positive opinion from the CHMP in Europe[2]. SPP635 is the most advanced compound in the SPP600 series and is one of several new proprietary renin inhibitors invented by Speedel Experimenta, the company's late-stage research unit.

Phase IIa results demonstrate strong efficacy and good tolerability
The trial had a double-blind, placebo-controlled, randomised, parallel design and it evaluated patients treated with a single dosage level of SPP635 once-daily for 4 weeks. It studied the safety and efficacy of SPP635 in 35 male and female patients (20 patients receiving SPP635 and 15 receiving placebo) with mild-to-moderate hypertension by measuring office and ambulatory blood pressure[3].

SPP635 was safe and well tolerated over the 4 week period. There were no serious adverse events reported nor were there any clinically significant changes in laboratory safety parameters. Sitting systolic blood pressure was significantly reduced by 17.9 mmHg from 156.6±9.1 mmHg at baseline (mean ± SD) to 138.7±13.3 mmHg in the SPP635 treated group after 4 weeks (p<0.001). The placebo group remained unchanged (156.1&plu
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
2. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
3. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
4. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
5. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
6. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
7. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
8. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
9. CytRx Reports Promising Data from Its Open-Label Extension Clinical Trial of Arimoclomol in ALS
10. Affymax Reports Phase 2 Clinical Dose Ranging Results of Once-Per-Month Hematide for the Treatment of Anemia
11. Bentley Reports Positive Results with Nasulin Intranasal Insulin Spray at the American Diabetes Association Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Speedel Reports Successful SPP635 Phase IIa Trial Hypertension
(Date:8/21/2014)... Aug. 21, 2014  The board of directors of ... provider of clinical trial imaging solutions, today announced that ... financial officer, effective immediately.  Mr. Groff has held the ... He joined VirtualScopics in January 2006 as an accounting ... "When the board of VirtualScopics asked Jim ...
(Date:8/21/2014)... (NASDAQ: CYBX ) today announced results for the ... 1   Operating results for the first quarter ... 2014, and other achievements, include: , Worldwide net product ... Strong international net sales of $13.2 million, an increase of ... product sales reached a new high of $58.8 million, an ...
(Date:8/20/2014)... Aug. 20, 2014 Northstar Global Business ... after months of hard work from many talented ... Snorenz formulation and package design.  The new formulation ... back into the product due to overwhelming evidence ... effects.  Snorenz Nighttime will also include these vitamins, ...
Breaking Medicine Technology:VirtualScopics, Inc. Names James Groff Chief Financial Officer 2VirtualScopics, Inc. Names James Groff Chief Financial Officer 3VirtualScopics, Inc. Names James Groff Chief Financial Officer 4Cyberonics Reports Fiscal 2015 First Quarter Results 2Cyberonics Reports Fiscal 2015 First Quarter Results 3Cyberonics Reports Fiscal 2015 First Quarter Results 4Cyberonics Reports Fiscal 2015 First Quarter Results 5Cyberonics Reports Fiscal 2015 First Quarter Results 6Cyberonics Reports Fiscal 2015 First Quarter Results 7Cyberonics Reports Fiscal 2015 First Quarter Results 8Cyberonics Reports Fiscal 2015 First Quarter Results 9Cyberonics Reports Fiscal 2015 First Quarter Results 10Cyberonics Reports Fiscal 2015 First Quarter Results 11Cyberonics Reports Fiscal 2015 First Quarter Results 12Cyberonics Reports Fiscal 2015 First Quarter Results 13Cyberonics Reports Fiscal 2015 First Quarter Results 14Cyberonics Reports Fiscal 2015 First Quarter Results 15Cyberonics Reports Fiscal 2015 First Quarter Results 16Northstar completes the first phase of its new retail strategy and prepares to ship reformulated Snorenz with all new packaging 2
... Mettler-Toledo International Inc. (NYSE: MTD ) today ... Life Sciences Conference in New York on Wednesday, September 21, ... webcast of the presentation, visit the investor relations page on ... of the webcast will be available for seven days. ...
... Sept. 14, 2011 Micross Components, a leading ... Deley as General Manager of its US Products ... in product and business development, will play a ... and its offerings to increase market share across ...
Cached Medicine Technology:Micross Components Names Mike Deley as General Manager of US Products & Services Division 2
(Date:8/21/2014)... 2014--Mesenchymal stem cells (MSCs) are present in virtually every ... regeneration after injury. But the theory that MSCs are ... following organ damage, and migrate to the site of ... provide conclusive evidence to resolve the controversy over the ... new study published in Stem Cells and Development ...
(Date:8/21/2014)... effective vaccination, polio is considered nearly eradicated. Each year ... scientists of the University of Bonn, together with colleagues ... that was able to resist the vaccine protection to ... outbreak in the Congo in 2010. The pathogen could ... results appear now in the magazine PNAS . ...
(Date:8/21/2014)... 21, 2014 Glioblastoma Multiforme Therapeutics ... Approaches Target High Unmet Need in Newly Diagnosed ... the Glioblastoma Multiforme (GBM) therapeutics market within the ... Japan. The report provides estimates of market size ... It also covers disease epidemiology, treatment algorithms, treatment ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 One of ... is likely to experience is an increasing adoption of ... the compliance of the patient through their convenient application, ... delivery system is a medical device used for the ... in the nose and paranasal sinus such as allergic ...
(Date:8/21/2014)... Hospital officials, community leaders and elected officials today ... building at Mount Sinai Queens, marking the completion of ... and modernization project. During the event, hospital officials ... Chairman of the nearby Kaufman Astoria Studios, for which ... be named. The project, which began late last ...
Breaking Medicine News(10 mins):Health News:Polio: Mutated virus breaches vaccine protection 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 2Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 3Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 4Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 5Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 6Health News:Asia-Pacific Glioblastoma Multiforme (GBM) Market Size Industry Analysis, Share, Growth, Trends and Forecast to 2020: MarketResearchReports.biz 7Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 2Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 3Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 4Health News:Intranasal Drug Delivery Market 2014 – 2018 Global Forecasts and Analysis in New Research Report at Sandlerresearch.org 5Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 2Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 3Health News:“Topping Off” Ceremony Marks Major Milestone in Mount Sinai Queens Construction Project 4
... , WASHINGTON, Sept. 9 Former presidential ... care address said Tuesday that he would be listening for ... willing to make to show that his promises of bipartisan ... The chairman of the Campaign for Working Families made the ...
... , , , BOSTON and ... its causes, potential cures, current treatments and strategies for living well ... Macular Degeneration Symposium on September 17. A free public educational program, ... the Barnstable Senior Center, 825 Falmouth Road (Rt. 28) in Hyannis. ...
... FLEMINGTON, N.J., Sept. 9 HCD Research announced ... Barack Obama,s speech on health care reform tonight to obtain ... care reform. , , (Logo: ... HCD Research will conduct the study using its MediaCurves.com(R) website ...
... , , LAKE MARY, ... nation,s largest independent specialty pharmacy providers, was again chosen as ... is the fifth consecutive year that Axium has received this ... Business Journal recognizes the top 100 privately held companies in ...
... , , PRINCETON, N.J., Sept. 9 ... ) today announced the opening of new clinical development offices in Sao ... global footprint with a comprehensive range of services across Latin America. Earlier ... These new sites will support staff in these countries, Central America, and ...
... pandemic may have antiviral properties, scientists say, , WEDNESDAY, Sept. ... sap has components that show great efficacy in killing off ... plant, Ferula assa-foetida , grows throughout Iran, Afghanistan and ... due to its ill-smelling sap. But the researchers note that ...
Cached Medicine News:Health News:Bauer Calls for News of Concrete Compromise from President Obama 2Health News:First Cape Cod Macular Degeneration Symposium To Be Held on September 17 2Health News:First Cape Cod Macular Degeneration Symposium To Be Held on September 17 3Health News:Research Firm will Obtain Americans' Reactions to the President's Speech on Health Care Reform 2Health News:Axium Healthcare Pharmacy, Inc. Has Been Chosen as One of 'Central Florida's Golden 100 Companies' for the Fifth Year in a Row 2Health News:Covance Opens New Clinical Development Offices in Brazil and Mexico 2Health News:Covance Opens New Clinical Development Offices in Brazil and Mexico 3
... The RSV OIA test features a ... your results. Approved for children under age ... provides an answer in just over 15 ... will enable you to decrease costs for ...
The GC OIA test is a rapid assay for the diagnosis of gonorrhea. Thermo solved the challenge of developing a specific rapid assay for Neisseria gonorrhea by using the proprietary ribosomal protein, ...
... A/B test combines performance equivalence to 14-day viral ... or B with a simple, easy-to-use test with ... has all the same procedural steps as our ... you decrease costs for unnecessary ancillary testing, improve ...
... Strep test delivers excellent sensitivity and specificity for ... simple, easy-to-use test that provides an answer in ... you to provide improved patient care with a ... laboratories. Find out what value we bring to ...
Medicine Products: